FGFR4 and Klotho Polymorphisms Are Not Associated with Cardiovascular Outcomes in Chronic Kidney Disease
Conclusion: rs351855 and rs9536314 were not associated with LVMI or cardiac events. These findings do not provide evidence for a relevant clinical role of either FGFR4 stimulation or soluble form of Klotho deficiency in LVH development.Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 21, 2021 Category: Neurology Source Type: research

Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease
Hyperuricemia predicts the development of chronic kidney disease (CKD) and metabolic complications, but whether it has a causal role has been controversial. This is especially true given the 2 recently conducted randomized controlled trials that failed to show a benefit of lowering uric acid in type 1 diabetes-associated CKD and subjects with stage 3 –4 CKD. While these studies suggest that use of urate-lowering drugs in unselected patients is unlikely to slow the progression of CKD, there are subsets of subjects with CKD where reducing uric acid synthesis may be beneficial. This may be the case in patients with gout...
Source: American Journal of Nephrology - October 21, 2021 Category: Neurology Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Am J Nephrol. 2021 Oct 8;52(9):702-713. doi: 10.1159/000519043. Online ahead of print.ABSTRACTINTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.METHODS: P...
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Am J Nephrol. 2021 Oct 8;52(9):702-713. doi: 10.1159/000519043. Online ahead of print.ABSTRACTINTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.METHODS: P...
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Am J Nephrol. 2021 Oct 8;52(9):702-713. doi: 10.1159/000519043. Online ahead of print.ABSTRACTINTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.METHODS: P...
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Am J Nephrol. 2021 Oct 8;52(9):702-713. doi: 10.1159/000519043. Online ahead of print.ABSTRACTINTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.METHODS: P...
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Am J Nephrol. 2021 Oct 8;52(9):702-713. doi: 10.1159/000519043. Online ahead of print.ABSTRACTINTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.METHODS: P...
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Am J Nephrol. 2021 Oct 8;52(9):702-713. doi: 10.1159/000519043. Online ahead of print.ABSTRACTINTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.METHODS: P...
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Am J Nephrol. 2021 Oct 8;52(9):702-713. doi: 10.1159/000519043. Online ahead of print.ABSTRACTINTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.METHODS: P...
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Conclusion: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 8, 2021 Category: Neurology Source Type: research

Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Am J Nephrol. 2021 Sep 17:1-9. doi: 10.1159/000518456. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.SUMMARY: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelin...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Panagiotis Theofilis Aikaterini Vordoni Maria Koukoulaki Georgios Vlachopanos Rigas G Kalaitzidis Source Type: research

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Am J Nephrol. 2021 Sep 16:1-13. doi: 10.1159/000518071. Online ahead of print.ABSTRACTINTRODUCTION: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japanese patients with renal anemia w...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients.PMID:34569494 | DOI:10.1159/000518399 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Daniel Erez Feda Fanadka Sydney Benchetrit Keren Cohen-Hagai Source Type: research

Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Am J Nephrol. 2021;52(8):666-672. doi: 10.1159/000518111. Epub 2021 Sep 16.ABSTRACTINTRODUCTION: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease.METHODS: This is a cross-sectional study based on data obtained in the 2005-2016 cycles of the National Health and Nutrition Examination Survey. We included all adult participants with available data on body mass index, estimated g...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Stefano Ciardullo Cinzia Ballabeni Roberto Trevisan Gianluca Perseghin Source Type: research

Estimation of Baseline Serum Creatinine with Machine Learning
CONCLUSION: Using machine learning models, baseline serum creatinine could be estimated with higher accuracy than the backcalculated estimated serum creatinine level.PMID:34569522 | DOI:10.1159/000518902 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Erina Ghosh Larry Eshelman Stephanie Lanius Emma Schwager Kalyan S Pasupathy Erin F Barreto Kianoush Kashani Source Type: research

Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Am J Nephrol. 2021 Sep 17:1-9. doi: 10.1159/000518456. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.SUMMARY: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelin...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Panagiotis Theofilis Aikaterini Vordoni Maria Koukoulaki Georgios Vlachopanos Rigas G Kalaitzidis Source Type: research

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Am J Nephrol. 2021 Sep 16:1-13. doi: 10.1159/000518071. Online ahead of print.ABSTRACTINTRODUCTION: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japanese patients with renal anemia w...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients.PMID:34569494 | DOI:10.1159/000518399 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Daniel Erez Feda Fanadka Sydney Benchetrit Keren Cohen-Hagai Source Type: research

Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Am J Nephrol. 2021 Sep 16;52(8):666-672. doi: 10.1159/000518111. Online ahead of print.ABSTRACTINTRODUCTION: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease.METHODS: This is a cross-sectional study based on data obtained in the 2005-2016 cycles of the National Health and Nutrition Examination Survey. We included all adult participants with available data on body mass index,...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Stefano Ciardullo Cinzia Ballabeni Roberto Trevisan Gianluca Perseghin Source Type: research

Estimation of Baseline Serum Creatinine with Machine Learning
CONCLUSION: Using machine learning models, baseline serum creatinine could be estimated with higher accuracy than the backcalculated estimated serum creatinine level.PMID:34569522 | DOI:10.1159/000518902 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Erina Ghosh Larry Eshelman Stephanie Lanius Emma Schwager Kalyan S Pasupathy Erin F Barreto Kianoush Kashani Source Type: research

Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Am J Nephrol. 2021 Sep 17:1-9. doi: 10.1159/000518456. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.SUMMARY: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelin...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Panagiotis Theofilis Aikaterini Vordoni Maria Koukoulaki Georgios Vlachopanos Rigas G Kalaitzidis Source Type: research

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Am J Nephrol. 2021 Sep 16:1-13. doi: 10.1159/000518071. Online ahead of print.ABSTRACTINTRODUCTION: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japanese patients with renal anemia w...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients.PMID:34569494 | DOI:10.1159/000518399 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Daniel Erez Feda Fanadka Sydney Benchetrit Keren Cohen-Hagai Source Type: research

Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Am J Nephrol. 2021 Sep 16;52(8):666-672. doi: 10.1159/000518111. Online ahead of print.ABSTRACTINTRODUCTION: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease.METHODS: This is a cross-sectional study based on data obtained in the 2005-2016 cycles of the National Health and Nutrition Examination Survey. We included all adult participants with available data on body mass index,...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Stefano Ciardullo Cinzia Ballabeni Roberto Trevisan Gianluca Perseghin Source Type: research

Estimation of Baseline Serum Creatinine with Machine Learning
CONCLUSION: Using machine learning models, baseline serum creatinine could be estimated with higher accuracy than the backcalculated estimated serum creatinine level.PMID:34569522 | DOI:10.1159/000518902 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Erina Ghosh Larry Eshelman Stephanie Lanius Emma Schwager Kalyan S Pasupathy Erin F Barreto Kianoush Kashani Source Type: research

Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Am J Nephrol. 2021 Sep 17:1-9. doi: 10.1159/000518456. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.SUMMARY: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelin...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Panagiotis Theofilis Aikaterini Vordoni Maria Koukoulaki Georgios Vlachopanos Rigas G Kalaitzidis Source Type: research

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Am J Nephrol. 2021 Sep 16:1-13. doi: 10.1159/000518071. Online ahead of print.ABSTRACTINTRODUCTION: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japanese patients with renal anemia w...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients.PMID:34569494 | DOI:10.1159/000518399 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Daniel Erez Feda Fanadka Sydney Benchetrit Keren Cohen-Hagai Source Type: research

Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Am J Nephrol. 2021 Sep 16;52(8):666-672. doi: 10.1159/000518111. Online ahead of print.ABSTRACTINTRODUCTION: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease.METHODS: This is a cross-sectional study based on data obtained in the 2005-2016 cycles of the National Health and Nutrition Examination Survey. We included all adult participants with available data on body mass index,...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Stefano Ciardullo Cinzia Ballabeni Roberto Trevisan Gianluca Perseghin Source Type: research

Estimation of Baseline Serum Creatinine with Machine Learning
CONCLUSION: Using machine learning models, baseline serum creatinine could be estimated with higher accuracy than the backcalculated estimated serum creatinine level.PMID:34569522 | DOI:10.1159/000518902 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Erina Ghosh Larry Eshelman Stephanie Lanius Emma Schwager Kalyan S Pasupathy Erin F Barreto Kianoush Kashani Source Type: research

Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Am J Nephrol. 2021 Sep 17:1-9. doi: 10.1159/000518456. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.SUMMARY: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelin...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Panagiotis Theofilis Aikaterini Vordoni Maria Koukoulaki Georgios Vlachopanos Rigas G Kalaitzidis Source Type: research

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Am J Nephrol. 2021 Sep 16:1-13. doi: 10.1159/000518071. Online ahead of print.ABSTRACTINTRODUCTION: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japanese patients with renal anemia w...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients.PMID:34569494 | DOI:10.1159/000518399 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Daniel Erez Feda Fanadka Sydney Benchetrit Keren Cohen-Hagai Source Type: research

Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Am J Nephrol. 2021 Sep 16;52(8):666-672. doi: 10.1159/000518111. Online ahead of print.ABSTRACTINTRODUCTION: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease.METHODS: This is a cross-sectional study based on data obtained in the 2005-2016 cycles of the National Health and Nutrition Examination Survey. We included all adult participants with available data on body mass index,...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Stefano Ciardullo Cinzia Ballabeni Roberto Trevisan Gianluca Perseghin Source Type: research

Estimation of Baseline Serum Creatinine with Machine Learning
CONCLUSION: Using machine learning models, baseline serum creatinine could be estimated with higher accuracy than the backcalculated estimated serum creatinine level.PMID:34569522 | DOI:10.1159/000518902 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Erina Ghosh Larry Eshelman Stephanie Lanius Emma Schwager Kalyan S Pasupathy Erin F Barreto Kianoush Kashani Source Type: research

Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Am J Nephrol. 2021 Sep 17:1-9. doi: 10.1159/000518456. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.SUMMARY: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelin...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Panagiotis Theofilis Aikaterini Vordoni Maria Koukoulaki Georgios Vlachopanos Rigas G Kalaitzidis Source Type: research

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Am J Nephrol. 2021 Sep 16:1-13. doi: 10.1159/000518071. Online ahead of print.ABSTRACTINTRODUCTION: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japanese patients with renal anemia w...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients.PMID:34569494 | DOI:10.1159/000518399 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Daniel Erez Feda Fanadka Sydney Benchetrit Keren Cohen-Hagai Source Type: research

Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Am J Nephrol. 2021 Sep 16;52(8):666-672. doi: 10.1159/000518111. Online ahead of print.ABSTRACTINTRODUCTION: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease.METHODS: This is a cross-sectional study based on data obtained in the 2005-2016 cycles of the National Health and Nutrition Examination Survey. We included all adult participants with available data on body mass index,...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Stefano Ciardullo Cinzia Ballabeni Roberto Trevisan Gianluca Perseghin Source Type: research

Estimation of Baseline Serum Creatinine with Machine Learning
CONCLUSION: Using machine learning models, baseline serum creatinine could be estimated with higher accuracy than the backcalculated estimated serum creatinine level.PMID:34569522 | DOI:10.1159/000518902 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Erina Ghosh Larry Eshelman Stephanie Lanius Emma Schwager Kalyan S Pasupathy Erin F Barreto Kianoush Kashani Source Type: research

Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Am J Nephrol. 2021 Sep 17:1-9. doi: 10.1159/000518456. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.SUMMARY: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelin...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Panagiotis Theofilis Aikaterini Vordoni Maria Koukoulaki Georgios Vlachopanos Rigas G Kalaitzidis Source Type: research

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Am J Nephrol. 2021 Sep 16:1-13. doi: 10.1159/000518071. Online ahead of print.ABSTRACTINTRODUCTION: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japanese patients with renal anemia w...
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research

The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients.PMID:34569494 | DOI:10.1159/000518399 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Daniel Erez Feda Fanadka Sydney Benchetrit Keren Cohen-Hagai Source Type: research